Contingency Tables Comparing 68Ga-DOTATATE PET/CT and 111In-Pentetreotide Imaging for All Patients (n = 78)
| 111In-pentetreotide | ||||||||
| Scan type | Cancer or progression, all types | Cancer or progression, SPECT/CT | Benign, all types | Benign, SPECT/CT | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) |
| 68Ga-DOTATATE PET/CT | ||||||||
| Cancer | 48 | 28 | 2 | 1 | ||||
| Benign | 2 | 1 | 26 | 18 | ||||
| 111In-pentetreotide | ||||||||
| Cancer | 36 | 24 | 2 | 1 | ||||
| Benign | 14 | 5 | 26 | 18 | ||||
| 68Ga-DOTATATE PET/CT | 96% (86–100) | 93% (77–99) | 96% (86–100) | 93% (77–99) | ||||
| 111In-pentetreotide, all types | 72% (58–75) | 93% (77–99) | 95% (82–99) | 65% (48–94) | ||||
Diagnosis based on single or multiple CT or MRI scans, surgical tissue confirmation, or combination thereof. Prevalence = 64% (95% CI, 52–75).
PPV = positive predictive value; NPV = negative predictive value.